Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21145396 | 1.00 | USP30 (0.43) | USP30RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20028889 | 0.85 | USP30 (0.47) | USP30RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20028690 | 0.85 | USP30 (0.47) | USP30RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21145361 | 0.81 | USP30 (0.39) | USP30RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL21145359 | 0.81 | USP30 (0.39) | USP30RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL21145378 | 0.79 | USP30 (0.55) | USP30RAB9ANPC1HPGD | |
| SCHEMBL21145376 | 0.79 | USP30 (0.55) | USP30RAB9ANPC1HPGD | |
| SCHEMBL21145358 | 0.78 | USP30 (0.74) | USP30 | |
| SCHEMBL21145356 | 0.78 | USP30 (0.74) | USP30 | |
| SCHEMBL21145350 | 0.77 | USP30 (0.75) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519397-B1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | USP30 1/4885RAB9A 3028/4885NPC1 3401/4885 |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | USP30 1/4885RAB9A 3028/4885NPC1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.